Reliance Global Group, Inc.

Reliance Global Group Reports First Quarter 2026 Results and Advances Scale51 Strategy Through Targeted Technology and Life Sciences Investments

Reliance Global Group Schedules First Quarter 2026 Financial Results and Business Update Conference Call

Reliance Global Group Launches LifeSci Global, Its Dedicated Life Sciences Platform, Partnering with Proven Operators Scott Korman and David Turner to Build and Lead the Platform with Innervate Radiopharmaceuticals as the First Platform Investment

Reliance Global Group Completes Transformative Investment in Late-Stage Radiopharmaceutical Innovator Innervate Through EZRA’s Biotech Division

Reliance Global Group Increases Ownership in Enquantum to 29% Following Achievement of Defined Technical and Commercial Milestones